Magellan Stem Cells
Magellan Stem Cells operates a specialized stem cell laboratory in Melbourne that provides stem cell services to doctors throughout Australia.
Magellan has developed stem cell treatments for osteoarthritis (OA). Magellan has already supplied stem cells for the treatment of OA in more than 600 patients. These treatments have been based on the culturing stem cells from each patient’s own cells.
Magellan has over the last four years been developing a stem cell treatment for osteoarthritis (OA) - using donor cells. The product is based on being able to treat OA with a single injection of donor stem cells into the effected joint(s). The products will be mass produced and supplied ‘off the shelf’ – and at ‘low cost’. Magellan is currently conducting clinical trials in order to obtain regulatory/marketing approval for the treatment of OA (knee) with donor cells.
Magellan In The News
A Stem Cell breakthrough has shown cartilage regrown reversing damage caused by degenerative conditions. Click above to find out more....
Overview:- Magellan is a world leader in respect to the supply of stem cells to clinicians to treat osteoarthritis (OA).
Magellan has been operating commercially in the supply of cultured autologous stem cells (using each patient’s own stem cells) to clinician’s in Australia and New Zealand since 2014.
Laboratory:- Magellan operates a stem cell laboratory that ‘manufactures’ (isolates and cultures) pure (‘expanded’) autologous stem cells. Magellan has cultured more than 100 billion stem cells for the ‘commercial’ treatment of patients with OA. Magellan is currently the only company offering such a service to doctors in Australia and New Zealand.
Treatments:- Magellan does not itself treat patients, operate a clinic and/or employ clinicians. Magellan operates a laboratory that processes/cultures stem cells on behalf of clinicians.
Magellan has currently processed stem cells for the treatment of more than 600 fee paying patients.
The vast majority of stem cells supplied by Magellan have been used for the treatment of patients with osteoarthritis.
The stem cell treatment of osteoarthritis is based on injections into each effected joint.
Clinical Results:- Magellan’s current autologous treatments for OA have shown the potential to provide for substantial pain relief, improvement in function, the halting of disease progression and the potential of delaying and/ or possibly eliminating the need for expensive joint replacement. Specialist Sports Physicians report that the clinical results of the treatments are far superior to any other alternative treatments for OA. There have been no reports of any serious adverse events.
Note - Such autologous treatments are, however, yet to be authorized for use in North America, Europe or Japan (except for clinical trials).
Magellan’s ‘value’ is in respect to its knowledge and experience in respect to the efficient and low- cost production (culturing) of stem cells – as well as the data and experience to enable identification of optimum donor cells from treatments since 2014.
Donor Cell Treatments
Strategy:- Magellan wishes to significantly increase the profitability of its stem cell operations by seeking regulatory approval/registration for a low cost ‘off the shelf’ stem cell treatment for osteoarthritis - based on the use of donor cells (‘allogeneic project’).
Status:- Magellan has commenced two Phase 1 clinical trials – Safety and Efficacy – re the treatment of osteoarthritis with ‘donor’ stem cells. The clinical trials commenced in July 2018 and are scheduled for completion in 2019.
The trials are based upon the use of ‘optimum’ allogeneic/donor cells selected from the 600 patients already treated with stem cells produced/supplied by Magellan.
Costs:- By being able to ‘mass produce’ large quantities of donor stem cells, the costs of ‘production’ will be able to be significantly reduced as a result of Magellan not needing to individually ‘culture’ each patient’s own stem cells (in small batch/ ‘high cost’ doses). In addition, the use of ‘donor cells’, will remove the need for patients to have ‘surgery/lipo-suction’ to collect their own stem cells. Costs:-
Clinical Outcomes: - The characteristics of stem cells vary from person to person. The most critical consideration in using donor stem cells is the selection of ‘optimum’ stem cells in respect of the clinical condition being treated.
It is believed – just as has been the case in the veterinary setting - that by being able to use especially selected ‘optimal’ donor stem cells, that the clinical outcomes (improvements) from stem cell treatments for osteoarthritis are likely to be even better than has been achieved with current autologous treatments.
The number of people suffering from OA in Australia exceeds 2 million – and is projected to be more than 3 million by 2030. (Refer Arthritis Market- Page 9). Magellan analysis shows that based on an assumed (illustrative only) annual Australian market penetration of only 5% of the approximately 2 million OA sufferers (100,000 patients per annum), the potential future profitable sales of Magellan could be in the range of AUS$150 – 200 million per annum (depending on the ultimate sales price for a dose of ‘donor cells’).
Science:- Magellan is in a unique position in that the government regulator (TGA) has allowed Magellan to supply ‘pure’ cultured stem cells to clinicians since 2014. Apart from sponsoring a number of clinical trials, Magellan has supplied stem cells for the treatment of more than 600 patients.
Magellan has been able to collect, collate, compare and analyse both the clinical data from the treatment of patients with osteoarthritis - as well as the ‘characteristics’ of the different ‘cell lines’. Magellan has now been able to use the data/clinical results to identify stem cell lines with the ‘optimum characteristics’ for the treatment of osteoarthritis.